Detalhe da pesquisa
1.
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Br J Haematol
; 190(6): 891-900, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239670
2.
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.
Blood
; 141(21): 2657-2661, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898087
3.
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Leukemia
; 38(3): 630-639, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272991
4.
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
Leukemia
; 33(5): 1102-1112, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30542144
5.
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
J Vis Exp
; (133)2018 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29553571
6.
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
PLoS One
; 9(9): e107587, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25244440
7.
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
J Clin Oncol
; 31(31): 3889-97, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24062400